Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety study of E. coli Nissle colibactin knockout versus wild-type E. coli Nissle in healthy volunteers
NL-OMON53774Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2023
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Randomised trial of escherichia coli nissle 1917 (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Adverse reactions, Inflammatory markers and 3 more. Started Sep 2023; status: active, not recruiting.
02
Drugs
escherichia coli nissle 1917
Beyond the preview
Go deeper on NL-OMON53774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53774.